Literature DB >> 20210644

Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections.

Rebecca J McClaine1, Thomas L Husted, Renee S Hebbeler-Clark, Joseph S Solomkin.   

Abstract

BACKGROUND: Many trials have been carried out to determine the effectiveness of antimicrobial agents in treating skin and soft tissue infections. The results of these studies are often utilized to make determinations about the use of these antimicrobials against other types of infections. Despite the importance of these trials in determining clinical care, we hypothesized that many of these studies failed to include a variety of infections of significant enough severity to effectively draw objective conclusions about antimicrobial efficacy.
METHODS: We conducted a modified PubMed search to identify studies of antimicrobial agents in treating soft tissue infections that were published from 1998 through 2008. We then evaluated these trials for specific recommended study criteria, which were based on published US Food and Drug Administration guidelines for the conduct of trials of antimicrobials for soft tissue infection.
RESULTS: Seventeen studies were identified for inclusion in the trial. Upon review, only 30% of trials required both local and systemic signs of infection for inclusion in the trial. One trial stratified results on the basis of operative intervention, less than half reported patient comorbidities, and only 53% provided a specific definition for "cure."
CONCLUSIONS: Our meta-analysis of current trials evaluating antimicrobial therapy for skin and soft tissue infections revealed substantial shortcomings in the design of most of these trials. These data provide evidence for the importance of designing specialist panels to objectively evaluate studies and photographs of included infections to ensure that conclusions drawn from these trials concerning clinical practice are justified.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20210644     DOI: 10.1086/651264

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

Review 1.  MRSA: treating people with infection.

Authors:  Nikolas Rae; Anna Jarchow-MacDonald; Dilip Nathwani; Charis Ann Marwick
Journal:  BMJ Clin Evid       Date:  2016-02-16

Review 2.  MRSA: treating people with infection.

Authors:  Dilip Nathwani; Peter Garnet Davey; Charis Ann Marwick
Journal:  BMJ Clin Evid       Date:  2010-10-28

Review 3.  [Bacterial skin and soft tissue infections].

Authors:  Frank Hanses
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

4.  A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.

Authors:  Inge C Gyssens; Matthew Dryden; Peter Kujath; Dilip Nathwani; Nicolaas Schaper; Barbara Hampel; Peter Reimnitz; Jeff Alder; Pierre Arvis
Journal:  J Antimicrob Chemother       Date:  2011-09-06       Impact factor: 5.790

Review 5.  Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin.

Authors:  Christian Eckmann; M Dryden
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

Review 6.  Interventions for necrotizing soft tissue infections in adults.

Authors:  Camille Hua; Romain Bosc; Emilie Sbidian; Nicolas De Prost; Carolyn Hughes; Patricia Jabre; Olivier Chosidow; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2018-05-31

7.  Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.

Authors:  N C Schaper; M Dryden; P Kujath; D Nathwani; P Arvis; P Reimnitz; J Alder; I C Gyssens
Journal:  Infection       Date:  2012-11-23       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.